ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

A deep learning model was able to predict future lung cancer risk from a single low-dose chest CT scan, according to new ...

A deep learning model was able to predict future lung cancer risk from a single low-dose chest CT scan, according to new research published at the ATS 2025 International Conference.

Dr. Samuel Rosner, a thoracic oncologist at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, said a growing number of people, particularly women under 65, are ...

At 34, non-smoker Reyna Savage mistook persistent shoulder pain for a gym injury, only to be diagnosed with stage 4 non-small ...

Zai Lab Limited ( NASDAQ: ZLAB) said on Monday that it received U.S. FDA fast track designation for its antibody-drug ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

A new study published in the Annals of Surgical Oncology revealed that individuals with little muscle mass, segmentectomy ...

OncoHost has won a €2.5m ($2.8m) grant to develop a novel biomarker capable of predicting cancer patient responses to immunotherapy.

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.